Molecular mechanisms of renal cell carcinoma metastasis and potential targets for therapy

被引：0

作者：

Li, Xinwei ^{[1
,2
]}

Xiong, Wei ^{[3
]}

Xiong, Zhiyong ^{[1
,2
]}

Zhang, Xiaoping ^{[1
,2
,4
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China

[2] Huazhong Univ Sci & Technol, Union Hosp, Inst Urol, Tongji Med Coll, Wuhan, Peoples R China

[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Nephrol, Wuhan, Peoples R China

[4] Shenzhen Huazhong Univ Sci & Technol, Res Inst, Shenzhen, Peoples R China

来源：

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2025年 / 13卷

基金：

中国国家自然科学基金;

关键词：

renal cell carcinoma; metastasis; metastatic renal cell carcinoma; molecular mechanisms; targeted therapy; PATHWAY; PROLIFERATION; CABOZANTINIB;

D O I：

10.3389/fcell.2025.1521151

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Renal cell carcinoma is a common type of cancer, with approximately 30% of patients potentially developing metastatic disease. Some patients with metastatic renal cell carcinoma are found in advanced stages, so the 5-year survival rate for metastatic renal cell carcinoma is only 14%. Currently, there are several drugs available for patients with metastatic renal cell carcinoma, and their overall survival can be extended to nearly 5 years. However, the sensitivity and efficacy of the treatment are still unsatisfactory. New targets and drugs to improve patient prognosis are urgently needed, but these are closely linked to the molecular mechanisms of renal cell carcinoma metastasis. In this review, we present the definition and common molecular mechanisms of metastatic renal cell carcinoma and provide new insights on their potential link to targeted therapies, which may enlighten scientists to develop future targeted therapeutic agents to improve the prognosis of patients with metastatic renal cell carcinoma.

引用

页数：9

共 98 条

[81] Evolution of cell therapy for renal cell carcinoma
Wang, Yufei
Suarez, Eloah Rabello
Kastrunes, Gabriella
de Campos, Najla Santos Pacheco
Abbas, Rabia
Pivetta, Renata Schmieder
Murugan, Nithyassree
Chalbatani, Ghanbar Mahmoodi
D'Andrea, Vincent
Marasco, Wayne A.
[J]. MOLECULAR CANCER, 2024, 23 (01)
[82] Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling
Wang, Zhixiang
[J]. CELLS, 2021, 10 (12)
[83] VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis
Wolf, Melissa M.
Madden, Matthew Z.
Arner, Emily N.
Bader, Jackie E.
Ye, Xiang
Vlach, Logan
Tigue, Megan L.
Landis, Madelyn D.
Jonker, Patrick B.
Hatem, Zaid
Steiner, KayLee K.
Gaines, Dakim K.
Reinfeld, Bradley I.
Hathaway, Emma S.
Xin, Fuxue
Tantawy, M. Noor
Haake, Scott M.
Jonasch, Eric
Muir, Alexander
Weiss, Vivian L.
Beckermann, Kathryn E.
Rathmell, W. Kimryn
Rathmell, Jeffrey C.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (08)
[84] Dysregulation and implications of N6-methyladenosine modification in renal cell carcinoma
Wu, Yaohai
Zhang, Shiqiang
Chen, Chujie
Pang, Jun
[J]. CURRENT UROLOGY, 2023, 17 (01) : 45 - 51
[85] Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Wu, Yige
Chen, Siqi
Yang, Xiaolu
Sato, Kazuhito
Lal, Preet
Wang, Yuefan
Shinkle, Andrew T.
Wendl, Michael C.
Primeau, Tina M.
Zhao, Yanyan
Gould, Alanna
Sun, Hua
Mudd, Jacqueline L.
Hoog, Jeremy
Mashl, R. Jay
Wyczalkowski, Matthew A.
Mo, Chia-Kuei
Liu, Ruiyang
Herndon, John M.
Davies, Sherri R.
Liu, Di
Ding, Xi
Evrard, Yvonne A.
Welm, Bryan E.
Lum, David
Koh, Mei Yee
Welm, Alana L.
Chuang, Jeffrey H.
Moscow, Jeffrey A.
Meric-Bernstam, Funda
Govindan, Ramaswamy
Li, Shunqiang
Hsieh, James
Fields, Ryan C.
Lim, Kian-Huat
Ma, Cynthia X.
Zhang, Hui
Ding, Li
Chen, Feng
[J]. CANCER RESEARCH, 2023, 83 (24) : 4161 - 4178
[86] Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma
Wu, Yige
Terekhanova, Nadezhda V.
Caravan, Wagma
Al Deen, Nataly Naser
Lal, Preet
Chen, Siqi
Mo, Chia-Kuei
Cao, Song
Li, Yize
Karpova, Alla
Liu, Ruiyang
Zhao, Yanyan
Shinkle, Andrew
Strunilin, Ilya
Weimholt, Cody
Sato, Kazuhito
Yao, Lijun
Serasanambati, Mamatha
Yang, Xiaolu
Wyczalkowski, Matthew
Zhu, Houxiang
Zhou, Daniel Cui
Jayasinghe, Reyka G.
Mendez, Daniel
Wendl, Michael C.
Clark, David
Newton, Chelsea
Ruan, Yijun
Reimers, Melissa A.
Pachynski, Russell K.
Kinsinger, Chris
Jewell, Scott
Chan, Daniel W.
Zhang, Hui
Chaudhuri, Aadel A.
Chheda, Milan G.
Humphreys, Benjamin D.
Mesri, Mehdi
Rodriguez, Henry
Hsieh, James J.
Ding, Li
Chen, Feng
[J]. NATURE COMMUNICATIONS, 2023, 14 (01)
[87] Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway
Xu, Zhipeng
Chen, Shuqiu
Liu, Ruiji
Chen, Hui
Xu, Bin
Xu, Weizhang
Chen, Ming
[J]. MOLECULAR CANCER, 2022, 21 (01)
[88] NF-κB and EGFR participate in S1PR3-mediated human renal cell carcinomas progression
Yan, Yali
Bao, Gegentuya
Pei, Jingyuan
Cao, Ying
Zhang, Chenyu
Zhao, Pengfei
Zhang, Yantao
Damirin, Alatangaole
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2022, 1868 (07):
[89] HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF-β and TNFSF13B/VEGF-A Axis
Yin, Lei
Li, Wenjia
Chen, Xuxiao
Wang, Ronghao
Zhang, Tao
Meng, Jialin
Li, Zhao
Xu, Li
Yin, Rui
Cheng, Bo
Yang, Huan
[J]. ADVANCED SCIENCE, 2023, 10 (17)
[90] SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway
Yin, Lei
Li, Wenjia
Xu, Aiming
Shi, Heng
Wang, Keyi
Yang, Huan
Wang, Ronghao
Peng, Bo
[J]. EBIOMEDICINE, 2020, 51

← 1 2 3 4 5 6 7 8 9 10 →